Company intelligence / Profile preview

Achilles Therapeutics UK Limited

Birmingham, West Midlands, United Kingdom

Ownership: Private
Employees: ~204
Development stage: Other

Overview

Achilles developed precision T cell therapies (cNeT) targeting patient-specific clonal neoantigens for solid tumors such as advanced NSCLC and melanoma. In early trials (CHIRON, THETIS), cNeT therapy demonstrated target engagement and was generally well tolerated in patients with advanced disease, but the company discontinued these programs in July 2024 due to strategic redirection.

Therapeutic areas: Oncology
Modalities: T cell therapyCell therapy
Industry: Biotech

Partnerships

Cancer Research Technology (Cancer Research UK subsidiary)UCL Business (University College London Business)Francis Crick Institute

Beyond the preview

Go deeper on Achilles Therapeutics UK Limited.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Achilles Therapeutics UK Limited.

Explore the full profile